Bruker (BRKR) Financials: History & Chart

Bruker Corporation(BRKR)

Medical - Devices · Billerica, MA

$60.83-3.03 (-4.75%)

Delayed quote: Oct 6, 2026, 2:15 PM EDT

About Bruker Corporation

Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.

Billerica, MA

11,085 employees

www.bruker.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Frank H. Laukien

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	3.50B	838.50M	823.40M	977.20M	860.50M	797.40M	801.40M	979.60M	864.40M
Cost of Goods Sold	1.87B	422.50M	434.10M	528.00M	481.10M	439.50M	410.20M	486.30M	445.60M
Gross Profit	1.63B	416.00M	389.30M	449.20M	379.40M	357.90M	391.20M	493.30M	418.80M
Gross Profit Margin	46.7%	49.6%	47.3%	46.0%	44.1%	44.9%	48.8%	50.4%	48.4%
Total Operating Expenses	1.51B	481.30M	344.30M	337.40M	344.40M	346.00M	359.40M	421.20M	350.70M
Research & Development	393.50M	94.30M	101.30M	99.60M	98.30M	100.20M	97.10M	104.40M	98.10M
Selling, General & Administrative	970.70M	238.90M	242.10M	247.20M	242.50M	231.40M	225.40M	236.80M	238.90M
Operating Income (EBIT)	126.50M	-65.30M	45.00M	111.80M	35.00M	11.90M	31.80M	72.10M	68.10M
Operating Margin	3.6%	-7.8%	5.5%	11.4%	4.1%	1.5%	4.0%	7.4%	7.9%
Income Before Tax (EBT)	-28.10M	-40.70M	18.20M	67.00M	-72.60M	1.10M	25.50M	54.60M	55.10M
Interest Income	4.90M	N/A	4.90M	N/A	N/A	2.90M	3.10M	2.40M	1.90M
Interest Expense	43.70M	N/A	12.20M	11.20M	20.30M	15.70M	13.10M	15.60M	11.60M
Other Income/Expense	-154.60M	24.60M	-26.80M	-44.80M	-107.60M	-10.80M	-6.30M	-17.50M	-13.00M
Net Income	-71.20M	-52.00M	14.40M	26.00M	-59.60M	7.60M	17.40M	13.70M	40.90M
Income Tax Expense	40.40M	14.20M	2.50M	37.80M	-14.10M	-3.10M	8.70M	40.70M	14.80M
Net Profit Margin	-2.0%	-6.2%	1.7%	2.7%	-6.9%	1.0%	2.2%	1.4%	4.7%
EBITDA	356.60M	-7.30M	103.30M	169.90M	90.70M	68.00M	82.20M	125.00M	119.10M
EBITDA Margin	10.2%	-0.9%	12.5%	17.4%	10.5%	8.5%	10.3%	12.8%	13.8%
Depreciation & Amortization	230.10M	58.00M	58.30M	58.10M	55.70M	56.10M	50.40M	52.90M	51.00M
EPS Basic	N/A	-0.41	0.02	N/A	-0.41	0.05	0.11	0.09	0.27
EPS Diluted	N/A	-0.41	0.02	N/A	-0.41	0.05	0.11	0.09	0.27
Weighted Average Basic Shares	152.20M	152.20M	152.20M	152.00M	151.80M	151.60M	151.60M	151.60M	151.50M
Weighted Average Diluted Shares	152.20M	152.20M	152.70M	152.50M	151.80M	151.70M	151.90M	152.00M	152.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3.44B	3.37B	2.96B	2.53B	2.42B	1.99B	2.07B	1.90B
Cost of Goods Sold	1.86B	1.72B	1.45B	1.23B	1.21B	1.05B	1.08B	995.60M
Gross Profit	1.58B	1.65B	1.51B	1.31B	1.21B	939.80M	995.30M	900.00M
Gross Profit Margin	45.9%	49.0%	51.0%	51.6%	50.0%	47.3%	48.0%	47.5%
Total Operating Expenses	1.34B	1.40B	1.08B	873.00M	796.30M	691.50M	694.40M	618.10M
Research & Development	395.20M	376.50M	294.80M	235.90M	220.80M	198.00M	187.70M	173.40M
Selling, General & Administrative	946.50M	893.80M	729.40M	607.40M	562.30M	477.80M	504.80M	444.70M
Operating Income (EBIT)	236.00M	253.10M	436.90M	432.70M	413.30M	248.30M	300.90M	262.40M
Operating Margin	6.9%	7.5%	14.7%	17.1%	17.1%	12.5%	14.5%	13.8%
Income Before Tax (EBT)	21.00M	205.20M	546.20M	414.90M	393.60M	225.80M	280.40M	244.70M
Interest Income	14.80M	9.30M	7.50M	2.80M	900K	3.20M	1.30M	1.20M
Interest Expense	60.30M	47.90M	16.40M	16.10M	14.30M	14.40M	16.00M	12.60M
Other Income/Expense	-215.00M	-47.90M	109.30M	-17.80M	-19.70M	-22.50M	-20.50M	-17.70M
Net Income	-8.60M	113.10M	427.20M	296.60M	277.10M	157.80M	197.20M	179.70M
Income Tax Expense	29.30M	91.40M	117.70M	116.40M	113.00M	64.40M	82.40M	63.70M
Net Profit Margin	-0.3%	3.4%	14.4%	11.7%	11.5%	7.9%	9.5%	9.5%
EBITDA	456.30M	436.90M	551.80M	521.40M	502.50M	328.70M	376.50M	327.30M
EBITDA Margin	13.3%	13.0%	18.6%	20.6%	20.8%	16.5%	18.2%	17.3%
Depreciation & Amortization	220.30M	183.80M	114.90M	88.70M	89.20M	80.40M	75.60M	64.90M
EPS Basic	-0.15	0.76	2.92	2.00	1.83	1.03	1.27	1.15
EPS Diluted	-0.15	0.76	2.90	1.99	1.81	1.02	1.26	1.14
Weighted Average Basic Shares	151.80M	149.00M	146.40M	148.60M	151.40M	153.40M	155.20M	156.20M
Weighted Average Diluted Shares	151.80M	149.50M	147.20M	149.40M	152.90M	154.60M	156.60M	157.20M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.